Vericel Still Hot?

Vericel Still Hot?
Shares of Vericel Corporation (VCEL) have gained an impressive 200% year-to-date, way ahead of the mere 0.9% returned by iShares Nasdaq Biotechnology ETF (IBB) for the same period. Vericel, formerly known as Aastrom Biosciences Inc., is focused on developing advanced cell therapies for the sports medicine and severe burn care markets. The Company currently markets two FDA approved autologous cell... Read More

All’s Well With VCEL, Time To Keep MOR In Mind, MYL Pulls Off Surprise

All’s Well With VCEL, Time To Keep MOR In Mind, MYL Pulls Off Surprise
The following are some of today’s top gainers in the pharma/biotech sector. 1. Vericel Corp. (VCEL) Gained 44.28% to close Tuesday’s (Nov.6) trading at $16.65. News: The Company reported narrower loss on 58% revenue growth for the third quarter of 2018, and raised its full year revenue guidance. Net loss for the third quarter ended September 30, 2018 narrowed to... Read More

CLSD Loses Shine, AVDL’s Q3 Results Disappoint, CWBR Briefly Suspends NASH Trial

CLSD Loses Shine, AVDL’s Q3 Results Disappoint, CWBR Briefly Suspends NASH Trial
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Clearside Biomedical Inc. (CLSD) Lost 62.77% to close Monday’s (Nov.5) trading at $2.07. News: The Company’s phase III study of combination therapy in Retinal Vein Occlusion did not meet its primary endpoint. The study, dubbed SAPPHIRE, investigated the superiority of XIPERE used together with... Read More

TRPX On A High, PBYI Braces For Busy Times Ahead, NVCN On Watch

TRPX On A High, PBYI Braces For Busy Times Ahead, NVCN On Watch
The following are some of today’s top gainers in the pharma/biotech sector. 1. Therapix Biosciences Ltd. (TRPX) Therapix Biosciences is a Canada-based specialty clinical-stage pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. Gained 37.31% to close Monday’s (Nov.5) trading at $9.20. News: No news Recent event: On October 24, the Company signed a binding letter... Read More

Child Birth In Space, Sniffing Out Malaria, Kepler Calls It Quits

Child Birth In Space, Sniffing Out Malaria, Kepler Calls It Quits
There should be no boundaries to human endeavor, said renowned physicist Stephen Hawking, and biotech company SpaceLife Origin is taking its cue from this quote. In this week’s “Did you know?” column, we are presenting news about SpaceLife Origin’s bold initiatives to colonize other planets, results of the world’s first study into dog’s ability to detect malaria, and NASA retiring... Read More

Puma Biotechnology’s stock plunges to pace premarket losers after key drug Nerlynx disappoints

Puma Biotechnology’s stock plunges to pace premarket losers after key drug Nerlynx disappoints
Shares of Puma Biotechnology Inc. PBYI, +4.18% plummeted 38% toward a 2 1/2-year low, to pace all premarket decliners, after the company reported third-quarter earnings and revenue that beat expectations, but reported disappointing results of its key product, the breast cancer treatment Nerlynx. That prompted J.P. Morgan to swing to bearish from bullish and slash its stock price target. Total... Read More

Stocks Move Sharply Higher On Optimism About Trade Talks – U.S. Commentary

Stocks Move Sharply Higher On Optimism About Trade Talks – U.S. Commentary
After initially showing a lack of direction, stocks moved sharply higher over the course of the trading session on Thursday. With the gains on the day, the major averages extended the strong upward move seen over the two previous sessions. The major averages ended the day just off their highs of the session. The Dow surged up 264.98 points or... Read More